title: Osteonecrosis of the Hip in Hematologic Disease: A Review of Conditions and Treatment Options.
abstract: Osteonecrosis of the hip can lead to advanced arthritis in typically young patients. Hematologic disorders comprise one group of potential causes. These include sickle cell anemia, hemophilia, aplastic anemia, thalassemia, and acute lymphoblastic leukemia. Depending on the stage of disease, treatment options include non-operative management, joint-preserving procedures (percutaneous drilling, core decompression, and vascularized or non-vascularized bone grafting), and joint arthroplasty (resurfacing arthroplasty and THA). Numerous small studies have investigated the efficacy of these options in patients who have specific hematologic disorders. Therefore, this report provides a comprehensive review of the osteonecrosis treatment options and results across the spectrum of patients who have various hematologic disorders.
authors: Rowan University School of Osteopathic Medicine, Stratford, New Jersey.
authors: Megan M
authors: MM
authors: Sorich
authors: Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
authors: Jeffery J
authors: JJ
authors: Cherian
authors: Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
authors: Mark J
authors: MJ
authors: McElroy
authors: Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, MD.
authors: Samik
authors: S
authors: Banerjee
authors: Johns Hopkins University, Center for Osteonecrosis Research and Education, Baltimore, Maryland.
authors: Lynne C
authors: LC
authors: Jones
authors: 9200 Rockville Pike, Clinical Center 5-5140, Bethesda, Maryland.
authors: Caterina P
authors: CP
authors: Minniti
authors: Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
authors: Michael A
authors: MA
authors: Mont
mesh_terms: D019644:Arthroplasty, Replacement, Hip; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016025:Bone Transplantation; D019299:Decompression, Surgical; D004164:Diphosphonates / Q000627:therapeutic use; D005271:Femur Head Necrosis / Q000209:etiology* / Q000628:therapy*; D006402:Hematologic Diseases / Q000150:complications*; D062785:Hemiarthroplasty; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use; D000077268:Pamidronate; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D014665:Vasodilator Agents; D016285:Iloprost; D000077268:Pamidronate